Sort
51,593 grants matching “hepatitis”
Structural studies with regulatory RNAs
$642,702Stuart F. J. Le Grice · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Plant-Derived hepatitis B Vaccine from Biomanufacturing System to Clinical Trial
$642,697Robert G. Britt · Quantum Tubers Corporation · R44 · FY2009 · HL
Lysosomal Regeneration (LysoGen) and Rescue as a Treatment for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
$642,653Mark W Grinstaff · Boston University (Charles River Campus) · R01 · FY2024 · DK
QUS Technology for Diagnosis and Grading of Hepatic Steatosis in NAFLD
$642,595Claude B Sirlin · University Of California, San Diego · R01 · FY2019 · DK
Mechanisms of HBV Functional Cure During Tenofovir-based ART in HIV/HBV Coinfection
$642,573Michael Jeffrey Vinikoor · University Of Alabama At Birmingham · R01 · FY2020 · AI
Hepatitis C Pathogenesis & The Human Genome
$642,486David L Thomas · Johns Hopkins University · R01 · FY2007 · DA
GENETICALLY MODIFIED HEPATOCYTES TO ACHIEVE SUCCESS IN LIVER CELL TRANSPLANTATION
$642,471David A Shafritz · Albert Einstein College Of Medicine, Inc · R01 · FY2016 · DK
PUFAs and gene variation affecting aspirin antiplatelet response
$642,386Kenneth E. Thummel · University Of Washington · P01 · FY2016 · GM
Molecular and Cellular Basis of PCB Developmental Neurotoxicity
$642,317Pamela J Lein · University Of California At Davis · R01 · FY2021 · ES
Improving Outcome in Patients with Advanced Intrahepatic Cholangiocarcinoma: A Randomized Phase II Study of Gemcitabine and Oxaliplatin With or Without Regional Floxuridine (FUDR)
$642,310William Robert Jarnagin · Sloan-Kettering Inst Can Research · U01 · FY2023 · CA
Body Composition & REE Responses to Bariatric Surgeries
$642,266Dympna Gallagher · Columbia University Health Sciences · R01 · FY2015 · DK
Lead optimization of Hepatitis B Virus ribonuclease H inhibitors
$642,207John E Tavis · Saint Louis University · R01 · FY2024 · AI
Therapeutic HBV vaccines with glucosidase inhibitors
$642,185Drexel University · U01 · FY2005 · AI
HIV, HCV, Hippo, and Liver Disease Progression
$642,162Raymond T Chung · Massachusetts General Hospital · R01 · FY2020 · AI
Evaluation Of Treatments Of Drug Dependence In HIV Infected Patients
$642,129Kenzie L Preston · National Institute On Drug Abuse · Z01 · FY2007 · DA
Immune correlates of protection against hepacivirus persistence.
$642,072Amit Kapoor · Research Inst Nationwide Children'S Hosp · R01 · FY2021 · AI
Leveraging electronic medical records to perform large-scale diabetes pharmacogenomics among ancestrally diverse patient populations
$642,048Keoki Williams · Henry Ford Health System · R01 · FY2017 · DK
Reducing morbidity and mortality from overdose, HIV, and hepatitis C in opioid-using persons
$641,983Ronald Scott Braithwaite · New York University School Of Medicine · R01 · FY2021 · DA
Prevalence of PAH in SCD Patients in Nigeria
$641,972Mark Thomas Gladwin · Heart, Lung, And Blood Institute · Z01 · FY2007 · HL
Mechanistic studies of nucleic acid enzymes involved in DNA replication, transcription, and innate immunity
$641,967Smita S Patel · Rbhs-Robert Wood Johnson Medical School · R35 · FY2017 · GM
A randomised study of interferon-free treatment for recently acquired hepatitis C in people who inject drugs and people with HIV coinfection (the REACT Study)
$641,939Gail Matthews · University Of New South Wales · R01 · FY2016 · DA
Predictors of treatment toxicity, failure, and relapse in HIV-related tuberculosis
$641,929Timothy R Sterling · Vanderbilt University Medical Center · R01 · FY2019 · AI
INSULIN RECEPTORS AND INSULIN ACTION
$641,802Vanderbilt University · R37 · FY2001 · DK
Association between pre-diagnosis hepatic fat infiltration and risk of liver metastasis and mortality in a large cohort of stage I-III colorectal cancer survivors
$641,777Edward Giovannucci · Harvard University D/B/A Harvard School Of Public Health · R01 · FY2024 · CA
Continuity of Care for Drug-Addicted Offenders in RI
$641,771Rhode Island Hospital (Providence, Ri) · U01 · FY2003 · DA